ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Leptomeningeal carcinomatosis in gastric cancer: a single-center retrospective analysis of 86 cases.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: extensive leptomeningeal metastasis from gastric cancer presenting with hearing impairment.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptomeningeal carcinomatosis (LMC) is a rare but highly lethal manifestation of gastric cancer. We sought to describe its clinical features and define prognostic factors in a large single-center cohort.
methodsWe retrospectively reviewed 86 patients diagnosed with LMC secondary to gastric cancer at Samsung Medical Center between 2008 and 2024.
resultsThe median interval from primary gastric cancer diagnosis to LMC development was 12.0 months (range, 0-106). Common presenting symptoms included headache (73.3%), nausea/vomiting (55.8%), and dizziness (48.8%). Primary gastric cancers were predominantly Borrmann type III (48.2%) or type IV (38.8%) and had an undifferentiated-type (96.5%) histology. Intrathecal (IT) methotrexate-based chemotherapy was administered to 54 patients (62.8%), with or without radiotherapy or systemic chemotherapy. Cytological response was seen in 14/54 patients (25.9%) who received IT chemotherapy. Decompressive therapies, including Ommaya reservoir, external ventricular drainage (EVD) and ventriculoperitoneal (VP) shunt were performed in 71/86 patients (82.6%). The median overall survival from LMC diagnosis was 6.0 weeks (95% confidence interval [CI]: 3.7-8.3). In multivariable analysis, age ≥ 60 years (HR 1.8) and ECOG PS > 2 (HR 2.8) were independent adverse prognostic factors. Univariable subgroup analyses demonstrated prolonged survival with intrathecal chemotherapy (HR 0.5), systemic chemotherapy (HR 0.4), and decompressive procedures (HR 0.3), whereas radiotherapy showed no significant benefit.
conclusionsThe prognosis of gastric cancer patients with LMC remains extremely poor, and older age and poor performance status were independent adverse prognostic factors. As intrathecal chemotherapy, systemic chemotherapy, and decompressive therapies may improve survival, an individualized, multidisciplinary treatment approach is recommended.
Indexed as
Identifiers
41364399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.